Companies › Glaceum
1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vutiglabridin | – | Phase 2 | Knee Osteoarthritis (Knee OA) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06845553 | Vutiglabridin | Phase 2 | Knee Osteoarthritis (Knee OA) | Immunology | Dec 2026 |
No annotated target.
–
Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines OrthoTrophix Resolve Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.